How FDA Clearance Changes Your Insurance Needs

Clearance is a regulatory milestone. For your insurance program, it’s a different company on the other side.

---

For a medtech startup, receiving 510(k) clearance or PMA approval feels like the finish line. Operationally, it’s the starting gun. The insurance program that carried you through R&D was built for a company with no commercial product in the field, and it rarely survives first contact with a hospital procurement team.

---

The Shift That Happens at Clearance

Before clearance, your core exposures are general liability, property, workers’ compensation, and clinical trial liability if you’re running a human study. Products liability isn’t absent, but it isn’t load-bearing yet.

At first commercial sale, products and completed operations coverage becomes the center of the program. Cyber matters as soon as the device connects or holds patient data, and D&O follows outside capital. Many startups are unprepared because their policy was bought for the old company.

---

How Your Exposure Changes: Clinical Use to Commercial Distribution

In a clinical study, a small number of devices are used under a protocol, at selected sites, with consented participants and close monitoring. Commercial distribution removes almost all of that containment.

Volume and spread. More units, more sites, more clinicians, more patients, often across several states.

Less control over use. Real-world use diverges from the protocol: off-label use, training gaps, maintenance lapses.

A longer chain. Distributors, hospitals, and clinicians sit between you and the patient, yet the manufacturer is almost always named in a claim.

A longer tail. Claims can surface years after a device ships, which makes policy trigger and continuity matter more than most founders expect. (We cover the fundamentals in Product Liability 101 for Medical Device Companies.)

---

What Distributors, GPOs, and Hospitals Require Before Onboarding

Your limits are rarely chosen by you. They’re set by whoever you’re selling through. Group purchasing organizations, hospital vendor agreements, and distributor contracts all attach insurance exhibits, and credentialing platforms check your certificate line by line before a rep can enter a facility or a purchase can proceed.

Requirements vary by contract, and you should always read the actual exhibit, but common asks include:

• Products and completed operations limits. Commonly in the range of several million to $10 million for GPO supplier agreements, and often higher for implantable or higher-risk devices.
• Additional insured status for the buyer, on products and completed operations, not just ongoing operations.
• Primary and non-contributory wording, so your policy responds first.
• Waiver of subrogation and a stated notice-of-cancellation period.

The most common failure point isn’t the dollar limit. It’s an additional insured endorsement that doesn’t extend to the product itself. A certificate that shows the right limit but the wrong endorsement gets rejected, and that’s often where a startup first discovers the gap, with a sale waiting.

---

The 3 Policy Updates to Make Before Your First Sale

1. Move to a true products and completed operations program. Confirm the policy covers your cleared device, that limits match your customer contracts rather than your funding stage, and that you understand the trigger (occurrence vs. claims-made), territory, and any exclusions for investigational or software-related claims.

2. Fix your endorsements. Make sure additional insured wording covers products and completed operations, and that primary and non-contributory, waiver of subrogation, and notice terms match what your contracts require. Have the broker test the actual certificate against each exhibit before you submit it.

3. Add recall expense coverage. Product liability responds to injury claims, not to the cost of pulling a device from the field. Recall expense is a separate coverage that’s frequently missing. Once units are in the market, it’s worth pricing before you need it. (See What Happens When a Medical Device Gets Recalled for how those costs and claims play out.)

---

Commercialization Readiness Checklist: The Insurance View

• Products and completed operations coverage in force, effective on or before first shipment
• Limits reviewed against every executed or pending GPO, hospital, and distributor agreement
• Additional insured, primary/non-contributory, waiver of subrogation, and notice terms confirmed on the actual certificate
• Policy trigger, territory, and exclusions reviewed with your broker, including software and connectivity
• Recall expense coverage priced and decided on, not assumed
• Cyber coverage evaluated if the device connects or stores patient data
• Tail or continuity plan for prior clinical trial coverage
• A review scheduled at each commercial milestone, not just at renewal

---

The Bottom Line

Clearance proves your device can be sold. Your insurance determines whether buyers will let you sell it, and whether one claim can end the company once you do. Treat it as part of the launch plan, not an afterthought.

Cleared and ready to commercialize? Make sure your coverage is too. [Link]

---

 

This article is for educational purposes only and does not constitute legal, regulatory, or insurance advice. Requirements vary by contract, device class, and carrier. Consult a licensed insurance professional with life sciences expertise.